

Examiner's Amendment

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it **MUST** be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Andrew Feinstein on 10/19/09.

1. In claims 51, 63, 65, 67, 69, 71, "for suppressing transcription of a Type I collagen gene, which comprises" is replaced with "comprising".
2. In claim 54 "improving" is replaced with "treating".
3. In claim 61, line 1, "An agent" is replaced with "A method"; in line 2, "administering" is inserted between "comprises" and "a" and "and an inert carrier" is replaced with "to a mammal in need thereof".
4. Claims 53, 56, 58 and 73 are deleted.

Telephone Inquiry

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Taofiq A. Solola, PhD. JD., whose telephone number is (571) 272-0709.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Janet Andres, can be reached on (571) 272-0867. The fax phone number for this Group is (571) 273-8300.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (571) 272-1600.

Application/Control Number: 10/572,639
Art Unit: 1625

Page 3

/Taofiq A. Solola/

Primary Examiner, 1625

October 19, 2009